Small molecules that induce protein-protein interactions to exert proximity-driven pharmacology such as targeted protein degradation are a powerful class of therapeutics. Molecular glues are of particular interest given their favorable size and chemical properties and represent the only clinically approved degrader drugs. The discovery and development of molecular glues for novel targets, however, remains challenging. Covalent strategies could in principle facilitate molecular glue discovery by stabilizing the neo-protein interfaces. Here, we present structural and mechanistic studies that define a -labeling covalent molecular glue mechanism, which we term "template-assisted covalent modification". We found that a novel series of BRD4 molecular glue degraders act by recruiting the CUL4 ligase to the second bromodomain of BRD4 (BRD4). BRD4, in complex with DCAF16, serves as a structural template to facilitate covalent modification of DCAF16, which stabilizes the BRD4-degrader-DCAF16 ternary complex formation and facilitates BRD4 degradation. A 2.2 Å cryo-electron microscopy structure of the ternary complex demonstrates that DCAF16 and BRD4 have pre-existing structural complementarity which optimally orients the reactive moiety of the degrader for DCAF16 covalent modification. Systematic mutagenesis of both DCAF16 and BRD4 revealed that the loop conformation around BRD4, rather than specific side chains, is critical for stable interaction with DCAF16 and BD2 selectivity. Together our work establishes "template-assisted covalent modification" as a mechanism for covalent molecular glues, which opens a new path to proximity driven pharmacology.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949066PMC
http://dx.doi.org/10.1101/2023.02.14.528208DOI Listing

Publication Analysis

Top Keywords

molecular glue
16
covalent modification
12
molecular glues
12
brd4
9
modification dcaf16
8
brd4 molecular
8
glue degraders
8
covalent molecular
8
"template-assisted covalent
8
covalent modification"
8

Similar Publications

Elucidation of the interaction between apo-transferrin and indisulam via multi-spectroscopic techniques and molecular modeling.

Spectrochim Acta A Mol Biomol Spectrosc

December 2024

School of Chemistry and Chemical Engineering, Nanchang University, Nanchang 330031, Jiangxi, China. Electronic address:

Apo-transferrin (apo-TRF) is a vital protein for maintaining iron balance in the body, which is produced by the liver. Indisulam (IDM) has been extensively used to treat cancer in clinical study and has been identified as a molecular glue. Iron imbalances in the body are believed to encourage the growth and spread of cancer cells.

View Article and Find Full Text PDF

Carbon Dots-Modified Hollow Mesoporous Photonic Crystal Materials for Sensitivity- and Selectivity-Enhanced Sensing of Chloroform Vapor.

Nanomicro Lett

December 2024

Department of Chemistry and Laboratory of Advanced Materials, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, State Key Laboratory of Molecular Engineering of Polymers, Collaborative Innovation Center of Chemistry for Energy Materials (2011-iChEM), College of Chemistry and Materials, Fudan University, Shanghai, People's Republic of China.

Chloroform and other volatile organic pollutants have garnered widespread attention from the public and researchers, because of their potential harm to the respiratory system, nervous system, skin, and eyes. However, research on chloroform vapor sensing is still in its early stages, primarily due to the lack of specific recognition motif. Here we report a mesoporous photonic crystal sensor incorporating carbon dots-based nanoreceptor (HMSS@CDs-PCs) for enhanced chloroform sensing.

View Article and Find Full Text PDF

This study focuses on spastic paraplegia type 50 (SPG50), an adapter protein complex 4 deficiency syndrome caused by mutations in the adapter protein complex 4 subunit mu-1 (AP4M1) gene, and on the downstream alterations of the AP4M1 protein. We applied a battery of heterogeneous computational resources, encompassing two in-house tools described here for the first time, to (a) assess the druggability potential of AP4M1, (b) characterize SPG50-associated mutations and their 3D scenario, (c) identify mutation-tailored drug candidates for SPG50, and (d) elucidate their mechanisms of action by means of structural considerations on homology models of the adapter protein complex 4 core. Altogether, the collected results indicate R367Q as the mutation with the most promising potential of being corrected by small-molecule drugs, and the flavonoid rutin as best candidate for this purpose.

View Article and Find Full Text PDF

Discovery of the first examples of right open reading frame kinase 2 (RIOK2) molecular glue degraders.

Eur J Med Chem

December 2024

College of Chemistry and Materials Science, Zhejiang Normal University, No. 688 Yingbin Road, Jinhua, Zhejiang Province, 321004, China; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, College of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510530, China. Electronic address:

Right open reading frame kinase 2 (RIOK2) is an atypical serine threonine kinase which plays an important role in regulating ribosome synthesis and cell cycle progression. RIOK2 has been implicated in multiple human cancers and is a potential target for cancer treatment. We previously reported the discovery of CQ211 as a potent and selective RIOK2 inhibitor.

View Article and Find Full Text PDF

G protein-coupled receptors (GPCRs), the largest family of drug targets, can signal through 16 subtypes of Gα proteins. Biased compounds that selectively activate therapy-relevant pathways promise to be safer, more effective medications. The determinants of bias are poorly understood, however, and rationally-designed, G protein-subtype-selective compounds are lacking.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!